Par Drugs & Chemicals Bhavnagar, India, Gujarat,Magnesium Salts,Aluminum Salts,Blended,Stearates,Silicates
过去5年,Par Drugs and Chemicals的股东应占净利润(持续经营业务)在September 2024达到了 182.7百万的峰值。 Par Drugs and Chemicals的股东应占净利润(持续经营业务)于March 2020触及5年低点,是47.65百万。 Par Drugs and Chemicals的股东应占净利润(持续经营业务)于2022 (92.133百万, -20.7%)减少和于2020 (47.65...
Par Drugs and Chemicals的ebitda减资本支出后的利息覆盖率于2020 (10.5x, +140.8%)、2021 (18.2x, +73.9%)、2022 (34.7x, +90.5%)和2023 (4,405.8x, +12,608.5%)增加。 相比竞争对手,Par Drugs的EBITDA减资本支出后的利息覆盖率基准如何? 隐藏这个小工具 ...
Par Drugs and Chemicals Ltd的平均价格/现金及短期投资(10年)排名为第48.7x名,处于板块内83.0%的水平。下表提供了更多数据的摘要: 板块医疗保健的平均价格/现金及短期投资(10年) 经济风险区类别 发展中 全部成分股 1,169 包括的成分股 1,123 分钟 1.2x 最大值 563.8x 中位数 14.1x 平均值 36.4x 标准差 ...
Par Drugs and Chemicals的无杠杆资产回报率于Maret 2020触及5年低点,是12.0%。 Par Drugs and Chemicals的无杠杆资产回报率于2022 (16.7%, -13.4%)减少和于2020 (12.0%, +21.9%)、2021 (19.3%, +61.0%)、2023 (17.9%, +6.8%)和2024 (20.4%, +13.9%)增加。
However, despite their safety, simultaneous treatment with two biologic drugs is rarely used, and literature data are often limited to case reports and series [51–54]. Significant knowledge gaps still exist on the potential overall risk for infectious complications compared with current standard of ...
Fibrates were widely used as a class of drugs for treating hyperlipidemia, which might lower serum triglycerides by 20-50%, lower LDLc by 10-15%, and increase HDLc by 10-15%. Experimental evidence indicated that the effects of fibrates on serum lipids were mediated through activation of PPAR...